Transurethral Resection of Non-muscle-invasive Bladder Cancer

被引:38
作者
Babjuk, Marko [1 ]
机构
[1] Charles Univ Prague, Fac Med 1, Gen Teaching Hosp, Dept Urol, Prague 12808 2, Czech Republic
关键词
Bladder cancer; Bladder tumours; Fluorescence cystoscopy; Narrow-band imaging; Non-muscle-invasive bladder cancer; Random biopsies; Recurrences; Re-TUR; TURB; Understaging; TRANSITIONAL-CELL-CARCINOMA; HEXAMINOLEVULINATE FLUORESCENCE CYSTOSCOPY; WHITE-LIGHT CYSTOSCOPY; IMMEDIATE POSTOPERATIVE INSTILLATION; UROTHELIAL CARCINOMA; PHASE-III; IN-SITU; TUMORS; RECURRENCE; RISK;
D O I
10.1016/j.eursup.2009.06.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Transurethral resection of the bladder (TURB) is the initial and critical step in the management of bladder tumours. The aim of the procedure is to establish the histologic diagnosis, determine the tumour stage and grade, and achieve complete removal of papillary non-muscle-invasive tumours. Although TURB is a frequently performed procedure, its results are limited by the high recurrence rate and by the risk of tumour understaging. The major prerequisite for optimal outcomes is a systematically and meticulously performed procedure by a well-trained urologist. Smaller tumours can be resected en bloc; tumours > 1 cm should be resected separately in fractions. Deep resection, including the detrusor muscle, is essential for correct staging, The biopsy should be taken from all areas suggestive of carcinoma in situ (CIS), and biopsies from normal-looking mucosa are recommended only in patients with positive cytology or non-papillary tumours. TURB should be performed with modern equipment, including new telescopes and video systems. Moreover, urologists should be aware of promising innovations, including new imaging techniques, and their possible benefits. Re-TUR can improve recurrence-free survival (RFS) and tumour staging. It is recommended in any patient with a T1 or high-grade tumour at initial resection and when the pathologist has reported that the specimen contained no muscle. It should also be considered in cases where the urologist is not sure that the initial resection was complete, especially in extensive and multiple tumours. (C) European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:542 / 548
页数:7
相关论文
共 46 条
  • [1] 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer
    Babjuk, M
    Soukup, V
    Petrík, R
    Jirsa, M
    Dvorácek, J
    [J]. BJU INTERNATIONAL, 2005, 96 (06) : 798 - 802
  • [2] EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder
    Babjuk, Marko
    Oosterlinck, Willem
    Sylvester, Richard
    Kaasinen, Eero
    Boehle, Andreas
    Palou-Redorta, Juan
    [J]. EUROPEAN UROLOGY, 2008, 54 (02) : 303 - 314
  • [3] The actual incidence of bladder perforation following transurethral bladder surgery
    Balbay, MD
    Çimentepe, E
    Ünsal, A
    Bayrak, Ö
    Koç, A
    Akbulut, Z
    [J]. JOURNAL OF UROLOGY, 2005, 174 (06) : 2260 - 2262
  • [4] Second resection and prognosis of primary high risk superficial bladder cancer: Is cystectomy often too early?
    Brauers, A
    Buettner, R
    Jakse, G
    [J]. JOURNAL OF UROLOGY, 2001, 165 (03) : 808 - 810
  • [5] Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies
    Brausi, M
    Collette, L
    Kurth, K
    van der Meijden, AP
    Oosterlinck, W
    Witjes, JA
    Newling, D
    Bouffioux, C
    Sylvester, RJ
    [J]. EUROPEAN UROLOGY, 2002, 41 (05) : 523 - 530
  • [6] Dedicated teaching programs can improve the quality of TUR of non-muscle-invasive bladder tumours (NMIBT): Experience of a single institution
    Brausi, M. A.
    Gavioli, M.
    Peracchia, G.
    Viola, M.
    Giliberto, G. L.
    Simonini, G.
    De Luca, G.
    Borelli, A.
    Bertom, V
    Verrini, G.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 180 - 180
  • [7] Early complications of endoscopic treatment for superficial bladder tumors
    Collado, A
    Chéchile, GE
    Salvador, J
    Vicente, J
    [J]. JOURNAL OF UROLOGY, 2000, 164 (05) : 1529 - 1532
  • [8] Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study
    Daniltchenko, DI
    Riedl, CR
    Sachs, MD
    Koenig, F
    Daha, KL
    Pflueger, H
    Loening, SA
    Schnorr, D
    [J]. JOURNAL OF UROLOGY, 2005, 174 (06) : 2129 - 2133
  • [9] Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study
    Denzinger, Stefan
    Burger, Maximilian
    Walter, Bernhard
    Knuechel, Ruth
    Roessler, Wolfgang
    Wieland, Wolf F.
    Filbeck, Thomas
    [J]. UROLOGY, 2007, 69 (04) : 675 - 679
  • [10] The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin:: A prospective, randomized clinical trial
    Divrik, RT
    Yildirim, Ü
    Zorlu, F
    Özen, H
    [J]. JOURNAL OF UROLOGY, 2006, 175 (05) : 1641 - 1644